Pink SheetThe Biden Administration’s policies on price inflation rebates in Medicare and Medicaid unintentionally provided President Trump a tool to amplify the threat tariffs would pose to pharma. But Trump’s
ScripCidara Therapeutics’ business outlook improved substantially on June 23 after releasing pre-market Phase IIb data for its non-vaccine seasonal influenza prevention agent showing better prophylaxis cap
ScripMerck & Co’s PD-1 inhibitor for multiple cancer indications Keytruda (pembrolizumab) comfortably retained its number one spot as the drug generating the highest global revenues in the first quarte
ScripHuntington’s disease (HD) has been a notoriously difficult field for drug development but enthusiasm is growing, not least at Skyhawk Therapeutics which has initiated a Phase II/III trial on a potenti